References

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

10.1097/hep.0000000000000520 · 2023 · External reference

Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis

10.1056/nejmra1503519 · 2017 · External reference

Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review

10.1016/j.jacc.2018.11.050 · 2019 · External reference

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

10.1053/j.gastro.2015.04.043 · 2015 · External reference

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

10.1002/hep.29085 · 2017 · External reference

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

10.1016/j.jhep.2017.07.027 · 2017 · External reference

NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances

10.1038/s41395-018-0088-6 · 2018 · External reference

Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States

10.1002/hep.30254 · 2019 · External reference

Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050

10.1001/jamanetworkopen.2024.54707 · 2025 · External reference

Toward Genetic Prediction of Nonalcoholic Fatty Liver Disease Trajectories: PNPLA3 and Beyond

10.1053/j.gastro.2020.01.053 · 2020 · External reference

Genetic and epigenetic factors determining NAFLD risk

10.1016/j.molmet.2020.101111 · 2021 · External reference

Therapeutic opportunities for the treatment of NASH with genetically validated targets

10.1016/j.jhep.2023.05.007 · 2023 · External reference

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

10.1038/ng.257 · 2008 · External reference

Pi*Z heterozygous alpha-1 antitrypsin states accelerate parenchymal but not biliary cirrhosis

10.1097/meg.0000000000000061 · 2014 · External reference

Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease

10.1038/ng.2901 · 2014 · External reference

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent

10.1053/j.gastro.2016.01.032 · 2016 · External reference

A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease

10.1056/nejmoa1712191 · 2018 · External reference

A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease

10.1371/journal.pgen.1008629 · 2020 · External reference

A genome-first approach to mortality and metabolic phenotypes in MTARC1 p.Ala165Thr (rs2642438) heterozygotes and homozygotes

10.1016/j.medj.2021.04.011 · 2021 · External reference

Selective Thyroid Hormone Receptor-Beta (TRbeta) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders

10.3389/fmed.2020.00331 · 2020 · External reference

Thyroid Hormone Mediated Modulation of Energy Expenditure

10.3390/ijms160716158 · 2015 · External reference

Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis

10.1089/thy.2021.0621 · 2022 · External reference

10.1021/jm4019299

10.1021/jm4019299 · 2014 · External reference

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

10.1056/nejmoa2309000 · 2024 · External reference

Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist

10.1016/j.atherosclerosis.2013.07.056 · 2013 · External reference

Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia

10.1016/j.jacc.2022.01.023 · 2022 · External reference

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

10.1038/s41591-023-02603-1 · 2023 · External reference

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

10.1016/s0140-6736(19)32517-6 · 2019 · External reference

Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population

10.1002/hep.31032 · 2020 · External reference

PNPLA3 Genotype and Risk of Liver and All-Cause Mortality

10.1002/hep.31113 · 2020 · External reference

Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population

10.1002/hep.31238 · 2020 · External reference

Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos

10.1111/liv.14387 · 2020 · External reference

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

10.1111/j.1464-5491.2006.01858.x · 2006 · External reference

Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease

10.1016/j.jhep.2021.10.013 · 2022 · External reference

Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

10.1002/hep.24283 · 2011 · External reference

Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis

10.1038/srep09284 · 2015 · External reference

The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease

10.1002/hep.23759 · 2010 · External reference

Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease

10.1194/jlr.p089953 · 2019 · External reference

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

10.1038/ncomms5309 · 2014 · External reference

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease

10.1002/hep.27490 · 2015 · External reference

Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial

10.1111/apt.70382 · 2025 · External reference

TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models

10.1016/j.jcmgh.2021.11.007 · 2022 · External reference

Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists

10.1089/thy.2018.0664 · 2019 · External reference

PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis

10.1016/j.jhep.2024.10.048 · 2025 · External reference

Unresolved reference

External reference

Consistent efficacy of efruxifermin across PNPLA3 genotypes in phase 2b trials in MASH

10.1097/hep.0000000000001792 · 2026 · External reference

Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial

10.1016/j.jhep.2026.03.021 · 2026 · External reference